{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:40:50Z","timestamp":1792874450556,"version":"4.5.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Department of Pharmaceuticals, the Ministry of Chemicals and Fertilizers, Government of India"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.apsb.2018.07.011","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T13:54:58Z","timestamp":1532613298000},"page":"733-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications"],"prefix":"10.1016","volume":"8","author":[{"given":"Eknath","family":"Ahire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Darshanwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2018.07.011_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.apsb.2015.11.005","article-title":"Injected nanocrystals for targeted drug delivery","volume":"6","author":"Lu","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2018.07.011_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijpharm.2010.07.044","article-title":"Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives","volume":"399","author":"Shegokar","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib3","series-title":"Nanomedicines: design, delivery and detection","author":"Braddock","year":"2016"},{"key":"10.1016\/j.apsb.2018.07.011_bib4","series-title":"Pharmaceutical suspensions","first-page":"285","article-title":"Solid nanosuspensions: the emerging technology and pharmaceutical applications as nanomedicine","author":"Verma","year":"2009"},{"key":"10.1016\/j.apsb.2018.07.011_bib5","series-title":"Emulsions and nanosuspensions for the formulation of poorly soluble drugs","author":"M\u00fcller","year":"1998"},{"key":"10.1016\/j.apsb.2018.07.011_bib6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nrd1550","article-title":"Drugs as materials: valuing physical form in drug discovery","volume":"3","author":"Gardner","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2018.07.011_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cossms.2012.10.004","article-title":"Nanocrystals for the parenteral delivery of poorly water-soluble drugs","volume":"16","author":"Sun","year":"2012","journal-title":"Curr Opin Solid State Mater Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib8","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/jps.24098","article-title":"A brief literature and patent review of nanosuspensions to a final drug product","volume":"103","author":"Chin","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib9","unstructured":"Nanotechnology for drug delivery: global market for nanocarriers. Available from: \u3008http:\/\/www.cientifica.com\/research\/market-reports\/nanotechnology-for-drug-delivery-global-market-for-nanocarriers\/\u3009."},{"key":"10.1016\/j.apsb.2018.07.011_bib10","unstructured":"Kanwar S. Nano medicine breakthrough a giant leap for India. Times India News. 24 August 2015. Available from: \u3008https:\/\/timesofindia.indiatimes.com\/home\/science\/Nano-medicine-breakthrough-a-giant-leap-for-India\/articleshow\/48646117.cms\u3009"},{"key":"10.1016\/j.apsb.2018.07.011_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future","volume":"47","author":"M\u00fcller","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2018.07.011_bib12","series-title":"Long acting injections and implants","first-page":"239","article-title":"Nanosuspensions","author":"Kumar","year":"2012"},{"key":"10.1016\/j.apsb.2018.07.011_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd1494","article-title":"Nanosuspensions in drug delivery","volume":"3","author":"Rabinow","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2018.07.011_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.coche.2011.12.001","article-title":"Pharmaceutical nanocrystals","volume":"1","author":"Wang","year":"2012","journal-title":"Curr Opin Chem Eng"},{"key":"10.1016\/j.apsb.2018.07.011_bib15","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ejps.2012.08.011","article-title":"Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of vitamin E TPGS and nanocrystal particle size on oral absorption","volume":"47","author":"Ghosh","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.colsurfb.2013.02.038","article-title":"Nanosuspension for parenteral delivery of a p-terphenyl derivative: preparation, characteristics and pharmacokinetic studies","volume":"108","author":"Tian","year":"2013","journal-title":"Colloid Surf B"},{"key":"10.1016\/j.apsb.2018.07.011_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijpharm.2014.04.060","article-title":"Nanocrystals of medium soluble actives\u2014Novel concept for improved dermal delivery and production strategy","volume":"470","author":"Zhai","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijpharm.2008.12.030","article-title":"Production and characterization of Hesperetin nanosuspensions for dermal delivery","volume":"371","author":"Mishra","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2007.02.030","article-title":"Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat","volume":"339","author":"Rabinow","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijpharm.2011.08.023","article-title":"Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal","volume":"420","author":"Zhang","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1166\/jbn.2013.1475","article-title":"Development and characterization of pilocarpine loaded Eudragit nanosuspensions for ocular drug delivery","volume":"9","author":"Khan","year":"2013","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.apsb.2018.07.011_bib22","series-title":"Ocular drug delivery systems: barriers and application of nanoparticulate systems","author":"Thassu","year":"2012"},{"key":"10.1016\/j.apsb.2018.07.011_bib23","first-page":"242","article-title":"Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface","volume":"7","author":"Das","year":"2011","journal-title":"Appl Amphotericin B Nanomed"},{"key":"10.1016\/j.apsb.2018.07.011_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2011.01.007","article-title":"State of the art of nanocrystals\u2013special features, production, nanotoxicology aspects and intracellular delivery","volume":"78","author":"M\u00fcller","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jconrel.2012.03.013","article-title":"Drug nanocrystals: in vivo performances","volume":"160","author":"Gao","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2018.07.011_bib26","first-page":"124","article-title":"Second generation of drug nanocrystals for delivery of poorly soluble drugs: smartcrystals technology","volume":"24","author":"Keck","year":"2008","journal-title":"Dosis"},{"key":"10.1016\/j.apsb.2018.07.011_bib27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijpharm.2011.02.051","article-title":"Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth","volume":"409","author":"Ghosh","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s11051-008-9357-4","article-title":"Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system","volume":"10","author":"Gao","year":"2008","journal-title":"J Nanopart Res"},{"key":"10.1016\/j.apsb.2018.07.011_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.addr.2011.03.011","article-title":"Production methods for nanodrug particles using the bottom-up approach","volume":"63","author":"Chan","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2018.07.011_bib30","first-page":"13","article-title":"Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs","volume":"10","author":"Junyaprasert","year":"2015","journal-title":"Asian J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2008.03.002","article-title":"A novel bottom\u2013up process to produce drug nanocrystals: controlled crystallization during freeze-drying","volume":"128","author":"De Waard","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2018.07.011_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2013.01.019","article-title":"Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size","volume":"453","author":"Sinha","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib33","first-page":"295","article-title":"Nanocrystal technology, drug delivery and clinical applications","volume":"3","author":"Junghanns","year":"2008","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2018.07.011_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2008.07.023","article-title":"Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products","volume":"364","author":"Van Eerdenbrugh","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/1872210510666161014122439","article-title":"Nanocrystal based drug delivery system: conventional and current scenario","volume":"11","author":"Thakkar","year":"2017","journal-title":"Recent Pat Nanotechnol"},{"key":"10.1016\/j.apsb.2018.07.011_bib36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2012.09.034","article-title":"Drug nanocrystals in the commercial pharmaceutical development process","volume":"453","author":"M\u00f6schwitzer","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejpb.2011.08.006","article-title":"Fabrication of quercetin nanocrystals: comparison of different methods","volume":"80","author":"Kakran","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejpb.2011.12.015","article-title":"Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches","volume":"81","author":"Salazar","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib39","unstructured":"Ryde NP, Ruddy SB, inventors. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate. United States patent US6375986B1; 2002."},{"key":"10.1016\/j.apsb.2018.07.011_bib40","unstructured":"Ryde T, Gustow EE, Ruddy SB, Jain R, Patel R, Wilkins MJ, inventors. Nanoparticulate fibrate formulations. United States patent US7276249B2; 2007."},{"key":"10.1016\/j.apsb.2018.07.011_bib41","unstructured":"Namburi RR, Kerr JE, inventors. Oral itraconazole formulations and methods of making the same. United States patent US20020150620A1; 2003."},{"key":"10.1016\/j.apsb.2018.07.011_bib42","unstructured":"Fran\u00e7ois MKJ, Dries WMAC, Basstanie EDG, inventors. Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters. United States patent US6555544B2; 2003."},{"key":"10.1016\/j.apsb.2018.07.011_bib43","unstructured":"Nagi AS, inventors. Rapamycin formulations for oral administration. United States patent US5989591A. 1999."},{"key":"10.1016\/j.apsb.2018.07.011_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijpharm.2012.07.055","article-title":"Sirolimus solid self-microemulsifying pellets: formulation development, characterization and bioavailability evaluation","volume":"438","author":"Hu","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib45","unstructured":"Pace GW, Mishra AK, Snow RA, Parikh I, Guivarc\u05f3h P-HW, inventors. Spray drying process and compositions of fenofibrate. United States patent US6696084B2; 2004."},{"key":"10.1016\/j.apsb.2018.07.011_bib46","unstructured":"Bosch HW, Liversidge E, Shelukar SD, Thompson KC, inventors. Pharmaceutical composition of a tachykinin receptor antagonist. United States patent US20040214746A1; 2012."},{"key":"10.1016\/j.apsb.2018.07.011_bib47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2018.07.011_bib48","article-title":"Nanosuspension for parenteral delivery","volume":"166","author":"Barret","year":"2007"},{"key":"10.1016\/j.apsb.2018.07.011_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/pharmaceutics8020016","article-title":"Stabilizing agents for drug nanocrystals: effect on bioavailability","volume":"8","author":"Tuomela","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2018.07.011_bib50","first-page":"7","article-title":"Nanosuspension: a novel approach toenhance solubility of poorly watersoluble drugs","author":"Shah","year":"2016","journal-title":"Pharma Sci Monit"},{"key":"10.1016\/j.apsb.2018.07.011_bib51","first-page":"84","article-title":"Itraconazole nanosuspension for oral delivery: formulation, characterization and in vitro comparison with marketed formulation","volume":"18","author":"Nakarani","year":"2010","journal-title":"Daru"},{"key":"10.1016\/j.apsb.2018.07.011_bib52","series-title":"Handbook of pharmaceutical excipients","first-page":"544","volume":"18","author":"Rowe","year":"2013"},{"key":"10.1016\/j.apsb.2018.07.011_bib53","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.msec.2015.01.033","article-title":"Co-delivery of docetaxel and Poloxamer 235 by PLGA\u2013TPGS nanoparticles for breast cancer treatment","volume":"49","author":"Tang","year":"2015","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.apsb.2018.07.011_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.colsurfb.2015.03.030","article-title":"Nevirapine loaded Poloxamer 407\/Pluronic P123 mixed micelles: optimization of formulation and in vitro evaluation","volume":"129","author":"Jindal","year":"2015","journal-title":"Colloid Surf B"},{"key":"10.1016\/j.apsb.2018.07.011_bib55","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jphp.12043","article-title":"Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel","volume":"65","author":"Chen","year":"2013","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2018.07.011_bib56","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.colsurfb.2016.05.094","article-title":"Evaluation of hydrogel composing of Pluronic F127 and carboxymethyl hexanoyl chitosan as injectable scaffold for tissue engineering applications","volume":"146","author":"Yap","year":"2016","journal-title":"Colloid Surf B"},{"key":"10.1016\/j.apsb.2018.07.011_bib57","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1021\/acs.langmuir.7b02279","article-title":"Quantifying binding of ethylene oxide\u2013propylene oxide block copolymers with lipid bilayers","volume":"33","author":"Zhang","year":"2017","journal-title":"Langmuir"},{"key":"10.1016\/j.apsb.2018.07.011_bib58","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s11095-014-1491-3","article-title":"Interaction studies between indomethacin nanocrystals and PEO\/PPO copolymer stabilizers","volume":"32","author":"Liu","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2018.07.011_bib59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jconrel.2013.08.006","article-title":"Stability of nanosuspensions in drug delivery","volume":"172","author":"Wang","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2018.07.011_bib60","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1039\/C7TB00134G","article-title":"Anti-cancer activity of camptothecin nanocrystals decorated by silver nanoparticles","volume":"5","author":"Zhan","year":"2017","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2018.07.011_bib61","first-page":"S10","article-title":"Dispersibility of spray-dried formulations for pulmonary drug delivery","volume":"56","author":"Li","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2018.07.011_bib62","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejps.2004.12.010","article-title":"Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion","volume":"24","author":"Lee","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib63","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cap.2005.01.012","article-title":"Role of polymeric stabilizers for drug nanocrystal dispersions","volume":"5","author":"Choi","year":"2005","journal-title":"Curr Appl Phys"},{"key":"10.1016\/j.apsb.2018.07.011_bib64","first-page":"1497","article-title":"Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery","volume":"6","author":"Wang","year":"2011","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2018.07.011_bib65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejpb.2015.02.031","article-title":"Process parameter dependent growth phenomena of naproxen nanosuspension manufactured by wet media milling","volume":"92","author":"Bitterlich","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejps.2016.03.003","article-title":"Development of a nanosuspension for iv administration: from miniscale screening to a freeze dried formulation","volume":"87","author":"Frank","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib67","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejpb.2014.05.014","article-title":"Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor","volume":"88","author":"Danhier","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib68","first-page":"1424","article-title":"Formulation and evaluation of paclitaxel nanocrystals for parenteral administration by using PVP","volume":"5","author":"Mahapatra","year":"2017","journal-title":"Int J Pharma Res Health Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib69","unstructured":"Electronic code of Federal Regulations: title 21 Food and Drugs Part 101 Food Labeling, 2017. Available from: \u3008https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=101\u3009."},{"key":"10.1016\/j.apsb.2018.07.011_bib70","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3109\/03639045.2015.1018275","article-title":"Enhanced oral bioavailability of paclitaxel by solid dispersion granulation","volume":"41","author":"Shanmugam","year":"2015","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib71","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.yrtph.2008.01.004","article-title":"Risk assessment for the amino acids taurine, l-glutamine and l-arginine","volume":"50","author":"Shao","year":"2008","journal-title":"Regul Toxicol Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib72","unstructured":"Arginine. Available from: \u3008http:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6322#Section=2D-structure\u3009. 27 December 2017."},{"key":"10.1016\/j.apsb.2018.07.011_bib73","series-title":"A consumer\u05f3s dictionary of food additives: descriptions in plain English of more than 12,000 ingredients both harmful and desirable found in foods","author":"Winter","year":"2009"},{"key":"10.1016\/j.apsb.2018.07.011_bib74","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/789765","article-title":"Soluplus graft copolymer: potential novel carrier polymer in electrospinning of nanofibrous drug delivery systems for wound therapy","volume":"2014","author":"Paaver","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.apsb.2018.07.011_bib75","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.powtec.2012.12.038","article-title":"Soluplus\u00ae: a novel polymeric solubilizer for optimization of Carvedilol solid dispersions: formulation design and effect of method of preparation","volume":"237","author":"Shamma","year":"2013","journal-title":"Powder Technol"},{"key":"10.1016\/j.apsb.2018.07.011_bib76","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejps.2013.02.006","article-title":"The applications of vitamin E TPGS in drug delivery","volume":"49","author":"Guo","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib77","unstructured":"Available from: \u3008https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm?Event=BasicSearch.page\u3009. (27-12-2017)."},{"key":"10.1016\/j.apsb.2018.07.011_bib78","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1016\/j.biomaterials.2012.03.046","article-title":"Vitamin E TPGS as a molecular biomaterial for drug delivery","volume":"33","author":"Zhang","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2018.07.011_bib79","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1016\/j.biomaterials.2009.02.045","article-title":"Poly(lactide) vitamin E derivative\/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel","volume":"30","author":"Feng","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2018.07.011_bib80","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1021\/mp100012s","article-title":"Paclitaxel nanocrystals for overcoming multidrug resistance in cancer","volume":"7","author":"Liu","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib81","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","article-title":"Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment","volume":"72","author":"Baert","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib82","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jddst.2015.08.001","article-title":"Enhanced oral bioavailability of ursolic acid nanoparticles via antisolvent precipitation with TPGS1000 as a stabilizer","volume":"29","author":"Ge","year":"2015","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.apsb.2018.07.011_bib83","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/mp060121r","article-title":"Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity","volume":"4","author":"Collnot","year":"2007","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib84","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/mp900191s","article-title":"Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access","volume":"7","author":"Collnot","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijpharm.2014.10.025","article-title":"Investigation of a nanosuspension stabilized by Soluplus\u00ae to improve bioavailability","volume":"477","author":"Yang","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib86","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejps.2011.11.025","article-title":"Soluplus\u00ae as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo","volume":"45","author":"Linn","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.2042-7158.2012.01587.x","article-title":"Hydroxypropylmethylcellulose films for the ophthalmic delivery of diclofenac sodium","volume":"65","author":"El\u2010Sousi","year":"2013","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2018.07.011_bib88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2014.03.048","article-title":"Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo","volume":"467","author":"Tuomela","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib89","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3109\/10837450.2012.723720","article-title":"Identification of critical process parameters and its interplay with nanosuspension formulation prepared by top down media milling technology\u2013a QbD perspective","volume":"18","author":"Ghosh","year":"2013","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.apsb.2018.07.011_bib90","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/nn9017558","article-title":"Multifunctional hydrophobin: toward functional coatings for drug nanoparticles","volume":"4","author":"Valo","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2018.07.011_bib91","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejps.2017.01.029","article-title":"Hydrophobin-nanofibrillated cellulose stabilized emulsions for encapsulation and release of BCS class II drugs","volume":"100","author":"Paukkonen","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib92","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bmcl.2015.12.060","article-title":"Development of curcumin\u2013cyclodextrin\/cellulose nanocrystals complexes: new anticancer drug delivery systems","volume":"26","author":"Ntoutoume","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2018.07.011_bib93","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejps.2010.04.006","article-title":"Preparation of stable nitrendipine nanosuspensions using the precipitation\u2013ultrasonication method for enhancement of dissolution and oral bioavailability","volume":"40","author":"Xia","year":"2010","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib94","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/IJN.S77731","article-title":"chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy","volume":"10","author":"Kurakula","year":"2015","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2018.07.011_bib95","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1166\/jbn.2016.2127","article-title":"The effect of surfactant on paclitaxel nanocrystals: an in vitro and in vivo study","volume":"12","author":"Liu","year":"2016","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.apsb.2018.07.011_bib96","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10717544.2013.871600","article-title":"Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery","volume":"22","author":"Wang","year":"2015","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2018.07.011_bib97","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3109\/03639045.2011.630394","article-title":"Preparation of azithromycin nanosuspensions by reactive precipitation method","volume":"38","author":"Hou","year":"2012","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib98","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jconrel.2011.12.005","article-title":"Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics","volume":"158","author":"Hill","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2018.07.011_bib99","doi-asserted-by":"crossref","first-page":"155104","DOI":"10.1088\/0957-4484\/21\/15\/155104","article-title":"In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery","volume":"21","author":"Wang","year":"2010","journal-title":"Nanotechnology"},{"key":"10.1016\/j.apsb.2018.07.011_bib100","first-page":"129","article-title":"Formulation, optimization and characterization of simvastatin nanosuspension prepared by nanoprecipitation technique","volume":"3","author":"Pandya","year":"2011","journal-title":"Pharm Lett"},{"key":"10.1016\/j.apsb.2018.07.011_bib101","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/45.1.77","article-title":"Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection","volume":"45","author":"Peters","year":"2000","journal-title":"J Antimicrob Chemotherapy"},{"key":"10.1016\/j.apsb.2018.07.011_bib102","first-page":"7397","article-title":"A toxic organic solvent-free technology for the preparation of PEGylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy","volume":"10","author":"Yin","year":"2015","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2018.07.011_bib103","doi-asserted-by":"crossref","first-page":"73083","DOI":"10.1039\/C6RA11260A","article-title":"Hyaluronic acid anchored paclitaxel nanocrystals improves chemotherapeutic efficacy and inhibits lung metastasis in tumor-bearing rat model","volume":"6","author":"Sharma","year":"2016","journal-title":"RSC Adv"},{"key":"10.1016\/j.apsb.2018.07.011_bib104","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10717544.2014.904455","article-title":"Preparation, in vitro and in vivo evaluation of bexarotene nanocrystals with surface modification by folate-chitosan conjugates","volume":"23","author":"Li","year":"2016","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2018.07.011_bib105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejps.2014.11.012","article-title":"Development of stabilized paclitaxel nanocrystals: in-vitro and in-vivo efficacy studies","volume":"69","author":"Sharma","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib106","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/03639045.2016.1225752","article-title":"Morphology, in vivo distribution and antitumor activity of bexarotene nanocrystals in lung cancer","volume":"43","author":"Wang","year":"2017","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2017.09.004","article-title":"A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-methyltryptophan nanocrystals and paclitaxel nanoparticles","author":"Calleja","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2018.07.011_bib108","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1556-276X-9-156","article-title":"Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity","volume":"9","author":"Chiang","year":"2014","journal-title":"Nanoscale Res Lett"},{"key":"10.1016\/j.apsb.2018.07.011_bib109","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.colsurfb.2013.06.004","article-title":"Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: i. Acute toxicity and pharmacokinetics studies","volume":"111","author":"Gao","year":"2013","journal-title":"Colloid Surf B"},{"key":"10.1016\/j.apsb.2018.07.011_bib110","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.colsurfb.2014.02.016","article-title":"Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: ii. Ability to reverse the drug-resistance of H460 human lung cancer cells","volume":"117","author":"Gao","year":"2014","journal-title":"Colloid Surf B"},{"key":"10.1016\/j.apsb.2018.07.011_bib111","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijpharm.2015.05.070","article-title":"Preparation and characterization of paclitaxel nanosuspension using novel emulsification method by combining high speed homogenizer and high pressure homogenization","volume":"490","author":"Li","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib112","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.colsurfb.2015.04.054","article-title":"The construction of puerarin nanocrystals and its pharmacokinetic and in vivo\u2013in vitro correlation (IVIVC) studies on beagle dog","volume":"133","author":"Yi","year":"2015","journal-title":"Colloid Surf B"},{"key":"10.1016\/j.apsb.2018.07.011_bib113","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1166\/jbn.2015.2158","article-title":"Pluronic F-127 stabilised docetaxel nanocrystals improve apoptosis by mitochondrial depolarization in breast cancer cells: pharmacokinetics and toxicity assessment","volume":"11","author":"Pawar","year":"2015","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.apsb.2018.07.011_bib114","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jps.21964","article-title":"Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability","volume":"99","author":"Onoue","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib115","unstructured":"Chow DS-L, Gupta P, Qi Y, Shah J, Wisniecki P, inventors. Parenteral and oral formulations of benzimidazoles. United States patent US20090048322A1; 2008."},{"key":"10.1016\/j.apsb.2018.07.011_bib116","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1211\/jpp.60.9.0006","article-title":"Distribution of an intravenous injectable nimodipine nanosuspension in mice","volume":"60","author":"Xiong","year":"2008","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2018.07.011_bib117","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2008.09.022","article-title":"Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery","volume":"367","author":"Ganta","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib118","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.nano.2010.10.012","article-title":"In vitro protein adsorption studies on nevirapine nanosuspensions for HIV\/AIDS chemotherapy","volume":"7","author":"Shegokar","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2018.07.011_bib119","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijpharm.2007.12.016","article-title":"Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions","volume":"355","author":"Gao","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11671-007-9063-7","article-title":"Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment","volume":"2","author":"Wahlstrom","year":"2007","journal-title":"Nanoscale Res Lett"},{"key":"10.1016\/j.apsb.2018.07.011_bib121","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000065608","article-title":"Enhanced ocular anti-inflammatory activity of ibuprofen carried by an eudragit RS100\u00ae nanoparticle suspension","volume":"34","author":"Bucolo","year":"2002","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.apsb.2018.07.011_bib122","first-page":"79","article-title":"Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution","author":"Dandagi","year":"2010","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.apsb.2018.07.011_bib123","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2007.03.011","article-title":"Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs","volume":"340","author":"Kassem","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib124","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/jps.21714","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the suitability of using fluticasone and an acute rat lung inflammation model to differentiate lung versus systemic efficacy","volume":"98","author":"Chiang","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib125","doi-asserted-by":"crossref","first-page":"510","DOI":"10.18433\/J3SW2T","article-title":"Sulfacetamide loaded Eudragit RL100 nanosuspension with potential for ocular delivery","volume":"13","author":"Mandal","year":"2010","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib126","doi-asserted-by":"crossref","first-page":"E192","DOI":"10.1208\/pt070127","article-title":"Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene","volume":"7","author":"Pignatello","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2018.07.011_bib127","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijpharm.2011.05.075","article-title":"Preparation and antitumor study of camptothecin nanocrystals","volume":"415","author":"Zhang","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib128","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s11095-012-0765-x","article-title":"Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment","volume":"29","author":"De Smet","year":"2012","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2018.07.011_bib129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1014276917363","article-title":"Production and characterization of a budesonide nanosuspension for pulmonary administration","volume":"19","author":"Jacobs","year":"2002","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2018.07.011_bib130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.colsurfb.2010.10.029","article-title":"Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension","volume":"83","author":"Wang","year":"2011","journal-title":"Colloid Surf B"},{"key":"10.1016\/j.apsb.2018.07.011_bib131","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10611860902718680","article-title":"The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis","volume":"17","author":"Shubar","year":"2009","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2018.07.011_bib132","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0378-5173(00)00622-0","article-title":"Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone","volume":"214","author":"Jacobs","year":"2001","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib133","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejpb.2004.03.022","article-title":"Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology","volume":"58","author":"M\u00f6schwitzer","year":"2004","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib134","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1166\/jbn.2011.1234","article-title":"Nanocrystallization of poorly water soluble drugs for parenteral administration","volume":"7","author":"Zakir","year":"2011","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.apsb.2018.07.011_bib135","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1021\/mp5001247","article-title":"Targeting of injectable drug nanocrystals","volume":"11","author":"Fuhrmann","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib136","unstructured":"Muller RH, Becker R, Kruss B, Peters K, inventors. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. United States patent US5858410A; 1999."},{"key":"10.1016\/j.apsb.2018.07.011_bib137","unstructured":"Grenier P, Vergnault G, Nhamias A, inventors. Nanoparticulate formulations of fenofibrate. PCT filling patent WO2003013474A1; 2014."},{"key":"10.1016\/j.apsb.2018.07.011_bib138","unstructured":"Vergnault G, Grenier P, Nhamias A, inventors. Novel compositions. United States patent US20040208936A1; 2002."},{"key":"10.1016\/j.apsb.2018.07.011_bib139","doi-asserted-by":"crossref","first-page":"10790","DOI":"10.1039\/C4NR07450E","article-title":"Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis","volume":"7","author":"Zhang","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2018.07.011_bib140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jddst.2016.02.006","article-title":"Production, applications and in vivo fate of drug nanocrystals","volume":"34","author":"Tuomela","year":"2016","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.apsb.2018.07.011_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03639045.2018.1460377","article-title":"Nanocrystal-based drug delivery system of risperidone: lyophilization and characterization","volume":"44","author":"Gol","year":"2018","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib142","doi-asserted-by":"crossref","unstructured":"Thakkar S, Sharma K, Khurana S, BansalA K. Excipients and their functionality for enabling technologies in oral dosage forms. Pharmaceutical excipients: properties, functionality, and applications in research and industry. Wiley Online Library; 2016.p.97\u2013143.","DOI":"10.1002\/9781118992432.ch3"},{"key":"10.1016\/j.apsb.2018.07.011_bib143","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1517\/17425247.2015.1043886","article-title":"Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations","volume":"12","author":"Leone","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2018.07.011_bib144","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2014.03.030","article-title":"Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery","volume":"183","author":"Pawar","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2018.07.011_bib145","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ejps.2013.03.010","article-title":"Oily nanosuspension for long-acting intramuscular delivery of curcumin didecanoate prodrug: preparation, characterization and in vivo evaluation","volume":"49","author":"Wei","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib146","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jconrel.2013.08.006","article-title":"Stability of nanosuspensions in drug delivery","volume":"172","author":"Wang","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2018.07.011_bib147","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3797\/scipharm.1103-17","article-title":"Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study","volume":"79","author":"Detroja","year":"2011","journal-title":"Sci Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib148","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejps.2010.03.003","article-title":"Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug","volume":"40","author":"Puri","year":"2010","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib149","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1208\/s12249-008-9170-5","article-title":"Downscaling drug nanosuspension production: processing aspects and physicochemical characterization","volume":"10","author":"Van Eerdenbrugh","year":"2009","journal-title":"AAPS Pharm Sci Tech"},{"key":"10.1016\/j.apsb.2018.07.011_bib150","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.addr.2011.02.001","article-title":"Physical and chemical stability of drug nanoparticles","volume":"63","author":"Wu","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2018.07.011_bib151","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijpharm.2010.12.027","article-title":"Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening","volume":"406","author":"Verma","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib152","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0378-5173(02)00040-6","article-title":"Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability","volume":"237","author":"M\u00fcller","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib153","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2010.11.009","article-title":"Preparation of a chemically stable quercetin formulation using nanosuspension technology","volume":"404","author":"Gao","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib154","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jps.22745","article-title":"Freeze-drying of nanosuspensions, part 3: investigation of factors compromising storage stability of highly concentrated drug nanosuspensions","volume":"101","author":"Beirowski","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2018.07.011_bib155","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1517\/17425247.2016.1142524","article-title":"Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders","volume":"13","author":"Malamatari","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2018.07.011_bib156","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1517\/17425247.2016.1142524","article-title":"Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders","volume":"13","author":"Malamatari","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2018.07.011_bib157","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/pharmaceutics5010107","article-title":"Steroid nanocrystals prepared using the Nano Spray Dryer B-90","volume":"5","author":"Baba","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2018.07.011_bib158","first-page":"3119","article-title":"Formulating food protein-stabilized indomethacin nanosuspensions into pellets by fluid-bed coating technology: physical characterization, redispersibility, and dissolution","volume":"8","author":"He","year":"2013","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2018.07.011_bib159","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijpharm.2011.08.026","article-title":"Lutein nanocrystals as antioxidant formulation for oral and dermal delivery","volume":"420","author":"Mitri","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2018.07.011_bib160","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s11095-011-0456-z","article-title":"Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods","volume":"28","author":"Laaksonen","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2018.07.011_bib161","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejps.2017.10.008","article-title":"Comparative evaluation of electrospraying and lyophilization techniques on solid state properties of Erlotinib nanocrystals: assessment of In-vitro cytotoxicity","volume":"111","author":"Thakkar","year":"2018","journal-title":"Eur J Pharm Sci"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383518301254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383518301254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:39:10Z","timestamp":1761928750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383518301254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":161,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S2211383518301254"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2018.07.011","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2018.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}